The Journal of Gene Medicine is an international gene therapy journal publishing advances in genetic medicine of relevance to genomics, oncology, neuroscience, virology and pharmacology, incorporating both basic and clinical studies. We welcome papers on DNA and RNA editing, genome editing tools, gene transfer, cell therapy, nanomedicine, and more.

Gene therapy clinical trials worldwide to 2023—an update

Gene therapy clinical trials worldwide to 2023—an update.

This review presents our analysis of clinical trials that, to the best of our knowledge, have been or are being performed worldwide. To date, 3,900 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide.

Articles

RESEARCH ARTICLE

Integrated Single‐Cell Transcriptome and eQTL Analyses Reveal the Role of PZP in Aging and Chronic Kidney Disease

  •  9 March 2025

Graphical Abstract

Integrated Single-Cell Transcriptome and eQTL Analyses Reveal the Role of PZP in Aging and Chronic Kidney Disease Issue 3, 2025

Aging and chronic kidney disease (CKD) share immune suppression and chronic inflammation as common hallmarks. This study reveals that PZP disrupts immune communication and drives metabolic reprogramming in CD8+ central memory T (TCM) cells, providing new insights into its role in disease progression and potential therapeutic implications.

RESEARCH ARTICLE

Characterization of Immune Landscape Based on Homologous Recombination Deficiency Associated Signatures and Identification of Knockdown of ERCC6L to Promote Radiosensitivity in Breast Cancer

  •  23 February 2025

Graphical Abstract

Characterization of Immune Landscape Based on Homologous Recombination Deficiency Associated Signatures and Identification of Knockdown of ERCC6L to Promote Radiosensitivity in Breast Cancer Issue 2, 2025

The illustrational workflow of this study. The article revolves around identifying markers associated with homologous recombination deficiency (HRD) for the development of prognostic model for breast cancer. Through various machine learning methods to construct the most predictive HRD-associated signatures on the prognosis and the efficacy of immunotherapy and radiotherapy and to reflect the immune microenvironment. Experiments elucidated the role of ERCC6L in enhancing radiation-induced apoptosis, cell cycle arrest and DNA damage to sensitizing cancer cells to radiotherapy.

RESEARCH ARTICLE

RNA Interference Targeting Small Heat Shock Protein B8 Failed to Improve Distal Hereditary Motor Neuropathy in the Mouse Model

  •  19 February 2025

Graphical Abstract

RNA Interference Targeting Small Heat Shock Protein B8 Failed to Improve Distal Hereditary Motor Neuropathy in the Mouse Model Issue 2, 2025

Mutations in HSPB8 cause distal hereditary motor neuropathy or axonal Charcot–Marie–Tooth disease. Mice expressing mutant Hspb8 mimic the disease, whereas mice lacking Hspb8 show no overt phenotype. We designed an RNAi treatment strategy to rescue mutant HSPB8 in patient-derived motor neurons and an Hspb8 knock-in mouse model of the disease. In patient-derived-induced pluripotent stem cells differentiated into motor neurons, reducing HSPB8 expression with a shRNA targeting its 3′UTR could improve mitochondrial morphology and fragmentation. However, adeno-associated virus-mediated treatment with the 3′UTR shRNA showed inconclusive results in terms of functional improvement in the knock-in mouse.

REVIEW ARTICLE
Open access

The Mechanisms, Research Status, and Future Prospects of m6A Modification in Breast Cancer

  •  19 February 2025

Graphical Abstract

The Mechanisms, Research Status, and Future Prospects of m6A Modification in Breast Cancer Issue 2, 2025

N6-methyladenosine (m6A) modification in eukaryotic RNAs has drawn much attention in breast cancer research recently. It impacts breast cancer's onset, progression, and prognosis via regulating RNA-related processes. m6A regulatory factors play key roles. Also, its interactions with non-coding RNAs and in the tumor microenvironment are of interest. Despite some known dual roles, its mechanisms need further study. This article summarizes the research to aid future research and clinical applications.

RESEARCH ARTICLE

FOXA3: A Novel Tumor Suppressor in Esophageal Squamous Cell Carcinoma

  •  18 February 2025

Graphical Abstract

FOXA3: A Novel Tumor Suppressor in Esophageal Squamous Cell Carcinoma Issue 2, 2025

This study investigates the role of FOXA3 in esophageal squamous cell carcinoma (ESCC). FOXA3 expression was significantly reduced in ESCC tissues and correlated with poor prognosis. Overexpression of FOXA3 inhibited ESCC cell proliferation, migration, and invasion in vitro and tumor growth in vivo. These findings suggest that FOXA3 acts as a tumor suppressor in ESCC and may serve as a potential diagnostic and therapeutic target.

RESEARCH ARTICLE

Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO‐1 Pathways

  •  18 February 2025

Graphical Abstract

Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways Issue 2, 2025

This study investigates the antitumor mechanisms of betulinic acid (BA) in gliomas. BA effectively inhibits the viability of U251 glioma cells. RNA sequencing showed that differentially expressed genes are enriched in the TNF, PI3K-Akt, and ferroptosis pathways. Molecular docking indicated that BA has a strong interaction with key molecules in the PI3K/AKT pathway. In vitro experiments confirmed that BA can induce ferroptosis in U251 cells, possibly by downregulating the phosphorylation levels of the PI3K/Akt pathway and increasing the expression levels of NRF2/HO-1. These findings suggest BA's potential as a novel therapeutic agent for gliomas by modulating multiple pathways.

REVIEW ARTICLE

Revealing the Complex Interaction of Noncoding RNAs, Sirtuin Family, and Mitochondrial Function

  •  22 January 2025

Graphical Abstract

Revealing the Complex Interaction of Noncoding RNAs, Sirtuin Family, and Mitochondrial Function Issue 1, 2025

This review focuses on the relationship between non-coding RNAs and the sirtuin (SIRT1-7) family and summarizes the impact of their interactions on mitochondrial metabolism, oxidative stress, mitochondrial apoptotic pathways, mitochondrial biogenesis, mitochondrial dynamics, and other mitochondria-related pathophysiological processes.

RESEARCH ARTICLE

Icariin Facilitates Osteogenic Differentiation and Suppresses Adipogenic Differentiation of Bone Marrow Mesenchymal Stem Cells by Enhancing SOST Methylation in Postmenopausal Osteoporosis

  •  22 January 2025

Graphical Abstract

Icariin Facilitates Osteogenic Differentiation and Suppresses Adipogenic Differentiation of Bone Marrow Mesenchymal Stem Cells by Enhancing SOST Methylation in Postmenopausal Osteoporosis Issue 1, 2025

This study investigates the mechanism of Icariin (ICA) in postmenopausal osteoporosis (PMO) rats. ICA increased bone mass and reduced bone marrow fat in ovariectomized (OVX) rats. It promoted osteogenic differentiation and inhibited adipogenic differentiation of bone marrow-derived stem cells (BMSCs). Overexpression of SOST countered ICA’s effects, whereas Wnt pathway activation with TWS119 restored them. ICA reduced SOST expression by diminishing ERα binding to its promoter, with methylation of SOST inhibiting this interaction. Overall, ICA enhances SOST methylation, promoting osteogenic differentiation in BMSCs.

RESEARCH ARTICLE

Idiopathic Pulmonary Fibrosis Is Associated With Type 1 Diabetes: A Two‐Sample Mendelian Randomization Study

  •  17 January 2025

Graphical Abstract

Idiopathic Pulmonary Fibrosis Is Associated With Type 1 Diabetes: A Two-Sample Mendelian Randomization Study Issue 1, 2025

This study used Mendelian randomization to explore the causal relationship between type 1 diabetes (T1D) and idiopathic pulmonary fibrosis (IPF). Analysis of genome-wide association study data revealed that T1D increases the risk of IPF (OR: 1.132, p = 0.005), with results remaining consistent after adjusting for aging. The findings suggest a potential causal link between T1D and IPF, meriting further investigation.

RESEARCH ARTICLE

Pericarpium Trichosanthis Inhibits TGF‐β1‐Smad3 Pathway‐Induced Cardiac Fibrosis in Heart Failure Rats via Upregulation of microRNA‐29b

  •  12 January 2025

Graphical Abstract

Pericarpium Trichosanthis Inhibits TGF-β1-Smad3 Pathway-Induced Cardiac Fibrosis in Heart Failure Rats via Upregulation of microRNA-29b Issue 1, 2025

Pericarpium Trichosanthis (PT) alleviates cardiac fibrosis and improves cardiac function in CHF rats. Moreover, PT could inhibit TGF-β1/Smad3 signaling by promoting the expression of miR-29b.

More articles
More articles
More articles

Recent issues

Latest news